Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes"

Venessa H M Tsang^{1

2

3}, Rachel T McGrath^{1

2}, Roderick J Clifton-Bligh^{1

2

3}, Richard A Scolyer^{4

5}, Valerie Jakrot⁴, Alexander D Guminski^{4

6}, Georgina V Long^{4

6}, Alexander M Menzies^{4

6}

Affiliations

¹ Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards Sydney, Australia.
² Sydney Medical School, Northern, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
³ Cancer Genetics Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, Sydney, NSW, Australia.
⁴ Melanoma Institute Australia and The University of Sydney, Sydney, Australia.
⁵ Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
⁶ Departments of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.

Comment

Venessa H M Tsang et al. J Clin Endocrinol Metab. 2020.

. 2020 Jun 1;105(6):e2317-e2318.

doi: 10.1210/clinem/dgaa144.

¹ Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards Sydney, Australia.
² Sydney Medical School, Northern, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
³ Cancer Genetics Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, Sydney, NSW, Australia.
⁴ Melanoma Institute Australia and The University of Sydney, Sydney, Australia.
⁵ Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
⁶ Departments of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.

No abstract available

Comment on

Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, Menzies AM. Tsang VHM, et al. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5499-5506. doi: 10.1210/jc.2019-00423. J Clin Endocrinol Metab. 2019. PMID: 31265074
Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes".
Kotwal A, Kudva YC. Kotwal A, et al. J Clin Endocrinol Metab. 2020 Jun 1;105(6):dgaa143. doi: 10.1210/clinem/dgaa143. J Clin Endocrinol Metab. 2020. PMID: 32188985 No abstract available.

1. Stamatouli AM, Quandt Z, Perdigoto AL, et al. . Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–1480. - PMC - PubMed
1. Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019;7(1):e000591. - PMC - PubMed
1. Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019;36(9):1075–1081. - PMC - PubMed
1. Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clinical Exp Immunol. 2020. - PMC - PubMed
1. Lu J, Yang J, Liang Y, Meng H, Zhao J, Zhang X. Incidence of immune checkpoint inhibitor-associated diabetes: a meta-analysis of randomized controlled studies. Front Pharmacol. 2019;10:1453. - PMC - PubMed